Bayer Buys Cancer-Fighting Antibody Rights For $426M

Law360, New York (December 1, 2009, 6:59 PM EST) -- Bayer Schering Pharma AG on Tuesday exercised an option to buy the rights to an innovative cancer treatment from American biopharmaceutical company Micromet Inc. for as much as $426 million.

Under the agreement, the two companies will develop a new BiTE antibody for the treatment of solid tumors in cancer patients. BiTE antibodies are used to direct the body's cytotoxic, or cell-destroying, T cells, to attack tumors, creating what Micromet said is a new therapeutic approach to treating cancer.

Bayer and Micromet first entered into an...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.